A photo of Alexei Grom.

Research Director, Division of Rheumatology

Professor, UC Department of Pediatrics

513-636-3339

513-636-3328

Board Certified

Make an Appointment

Visit the Grom-Thorton Research Lab

My Biography & Research

Biography

My early work with outstanding mentors, who were pediatric rheumatologists, led me to pursue my clinical and research interests. During my fellowship, the unfortunate death of a patient from macrophage activation syndrome (MAS) prompted me to further study this life-threatening complication of systemic juvenile idiopathic arthritis.

Currently, I focus on identifying risk factors and new therapeutic targets in MAS. Our transnational studies have identified interferon gamma (INF), a dimerized soluble cytokine, as a therapeutic target in patients suffering from MAS. This discovery provided the rationale for a new clinical trial that is currently underway.

My research is funded by the National Institutes of Health (NIH) and the Systemic Juvenile Idiopathic Arthritis (SJIA) Foundation. I have also received research grants from Sobi, Novartis and AB2Bio.

Additional Languages

French, Russian

Academic Affiliation

Professor, UC Department of Pediatrics

Clinical Divisions

Rheumatology, Lupus

Research Divisions

Rheumatology



Blog Posts

My Education

MD: Leningrad (St. Petersburg) Pediatric Medical Institute, Russia, 1986.

Residency: Leningrad (St. Petersburg) Medical Institute, Russia, 1988; Children's Hospital Medical Center, Cincinnati, OH, 1998.

Fellowship: Leningrad (St. Petersburg) Pediatric Medical Institute, Russia, 1991; Children's Hospital Medical Center, Cincinnati, OH, 1995.

Certification: Pediatrics, 1999.

My Publications

The use of S100 proteins testing in juvenile idiopathic arthritis and autoinflammatory diseases in a pediatric clinical setting: A retrospective analysis. Aljaberi, N; Tronconi, E; Schulert, G; Grom, AA; Lovell, DJ; Huggins, JL; Henrickson, M; Brunner, HI. Pediatric Rheumatology Online Journal. 2020; 18.

A novel STING1 variant causes a recessive form of STING-associated vasculopathy with onset in infancy (SAVI). Lin, B; Berard, R; Al Rasheed, A; Aladba, B; Kranzusch, PJ; Henderlight, M; Grom, A; Kahle, D; Torreggiani, S; Aue, AG; et al. Journal of Allergy and Clinical Immunology. 2020; 146:1204-1208.e6.

Proceedings from the 2ndNext Gen Therapies for Systemic Juvenile Idiopathic Arthritis and Macrophage Activation Syndrome symposium held on October 3-4, 2019. Canna, SW; Schulert, GS; de Jesus, A; Pickering, A; Brunner, H; Gadina, M; Levine, S; Goldbach-Mansky, R; Boutelle, J; Sinha, R; et al. Pediatric Rheumatology Online Journal. 2020; 18.

On the Alert for Cytokine Storm: Immunopathology in COVID-19. Henderson, LA; Canna, SW; Schulert, GS; Volpi, S; Lee, PY; Kernan, KF; Caricchio, R; Mahmud, S; Hazen, MM; Halyabar, O; et al. Arthritis and Rheumatology. 2020; 72:1059-1063.

Emapalumab in children with primary hemophagocytic lymphohistiocytosis. Locatelli, F; Jordan, MB; Allen, C; Cesaro, S; Rizzari, C; Rao, A; Degar, B; Garrington, TP; Sevilla, J; Putti, M; et al. The New England journal of medicine. 2020; 382:1811-1822.

Distinct interferon signatures and cytokine patterns define additional systemic autoinflammatory diseases. de Jesus, AA; Hou, Y; Brooks, S; Malle, L; Biancotto, A; Huang, Y; Calvo, KR; Marrero, B; Moir, S; Oler, AJ; et al. Journal of Clinical Investigation. 2020; 130:1669-1682.

Synergistic Signaling of TLR and IFNα/β Facilitates Escape of IL-18 Expression from Endotoxin Tolerance. Verweyen, E; Holzinger, D; Weinhage, T; Hinze, C; Wittkowski, H; Pickkers, P; Albeituni, S; Verbist, K; Nichols, KE; Schulert, G; et al. American Journal of Respiratory and Critical Care Medicine. 2020; 201:526-539.

IL-18 as a biomarker linking systemic juvenile idiopathic arthritis and macrophage activation syndrome. Yasin, S; Fall, N; Brown, RA; Henderlight, M; Canna, SW; Girard-Guyonvarc'h, C; Gabay, C; Grom, AA; Schulert, GS. Rheumatology. 2020; 59:361-366.

IL-18 as therapeutic target in a patient with resistant systemic juvenile idiopathic arthritis and recurrent macrophage activation syndrome. Yasin, S; Solomon, K; Canna, SW; Girard-Guyonvarc'h, C; Gabay, C; Schiffrin, E; Sleight, A; Grom, AA; Schulert, GS. Rheumatology. 2020; 59:442-445.

Emergent high fatality lung disease in systemic juvenile arthritis. Saper, VE; Chen, G; Deutsch, GH; Guillerman, RP; Birgmeier, J; Jagadeesh, K; Canna, S; Schulert, G; Deterding, R; Xu, J; et al. Annals of the Rheumatic Diseases. 2019; 78:1722-1731.